Boehringer Ingelheim, Pfizer to Jointly Market Once-A-Day Spiriva(R) for Chronic Obstructive Pulmonary Disease

INGELHEIM, Germany and NEW YORK, April 11

Apr 11, 2001, 01:00 ET from Pfizer Inc

/PRNewswire Interactive News Release/ -- Boehringer Ingelheim and Pfizer Inc
 announced today that they have entered into a long-term worldwide agreement to
 jointly market Spiriva(R) (tiotropium), a novel once-a-day inhaled treatment
 for Chronic Obstructive Pulmonary Disease (COPD), which includes chronic
 bronchitis and emphysema.
     Boehringer Ingelheim has filed for marketing approval with regulatory
 authorities in Europe, where Spiriva(R) could be available as early as mid-
 2002.  A new drug application for Spiriva(R) is anticipated to be filed with
 the Food and Drug Administration later this year.
     Spiriva(R), discovered and developed by Boehringer Ingelheim, would be the
 first once-a-day inhaled bronchodilator treatment for COPD and represents a
 significant advance over other treatment options.   With Atrovent(R) and
 Combivent(R), Boehringer Ingelheim already markets two leading medications for
 COPD worldwide.
     According to the World Health Organization, about 600 million people
 suffer from COPD, though many are undiagnosed.  The disease claims three
 million lives annually.  It is estimated that one in five smokers will develop
 COPD.
     "We're very pleased to be working with Pfizer in co-promoting Spiriva(R),"
 said Prof. Rolf Krebs, Chairman of the Board of Managing Directors at
 Boehringer Ingelheim.  "Through this agreement, we gain a strong and
 experienced partner who will help increase awareness of the disease and of the
 significant patient benefits that this novel compound delivers."
     "We fully expect Spiriva(R) to be an important treatment option for a
 condition that is debilitating to patients and costly to health care systems
 worldwide," said Pfizer Chief Executive Officer Hank McKinnell.  "Building on
 our extensive partnering experience and combined with Boehringer Ingelheim's
 established strength and long experience in respiratory disease management,
 Spiriva(R) should become the global leader in treating COPD."
     COPD is a chronic respiratory disorder characterized by limited airflow
 accompanied by symptoms such as shortness of breath, cough, wheezing and
 increased sputum production.  As the disease progresses, patients become
 increasingly disabled, although at first they may attribute their symptoms to
 aging.  Currently there are no specific medications that are fully effective
 in treating COPD.
     Data from clinical trials involving more than 3,000 patients worldwide
 have demonstrated that Spiriva(R) is highly effective, providing sustained
 bronchodilation with significant symptomatic improvement in shortness of
 breath.  Data also indicate that Spiriva(R) reduced exacerbations of COPD,
 resulting in fewer hospitalizations.  Spiriva(R) also was shown to be well
 tolerated.
     Under terms of the agreement, Boehringer Ingelheim and Pfizer will conduct
 additional clinical trials and further develop Spiriva(R).
     "We anticipate this will be a long and productive collaboration with
 Pfizer in the commercialization of Spiriva(R)," said Dr. Alessandro Banchi,
 Member of Boehringer Ingelheim's Board of Managing Directors who is
 responsible for pharmaceutical marketing and sales.
 
     The Boehringer Ingelheim group of companies, with headquarters in
 Ingelheim, Germany, is one of the 20 leading pharmaceutical companies in the
 world.  In 2000, it posted revenues of more than EUR 6 billion.  Boehringer
 has some 140 affiliated companies worldwide.  The focus is on the human
 pharmaceutical and animal health businesses.  The human pharmaceutical
 business, which accounts for 95 percent of sales, mainly includes prescription
 medicines and products for consumer health care but also products for
 industrial customers (chemicals and biopharmaceuticals).
     Substantial research and development, production, and distribution
 facilities are located around the globe.  In 2000, Boehringer-Ingelheim spent
 EUR 1 billion on research and development, equivalent to 16 percent of net
 sales.
 
     Pfizer Inc discovers, develops, manufactures and markets leading
 prescription medicines for humans and animals, and many of the world's best-
 known consumer products.  Pfizer had global revenues of $29.6 billion in 2000.
 Pfizer plans to make a research and development investment of approximately
 $5 billion in 2001.
 
     COPD FACTS
 
     The Disease
 
     Chronic Obstructive Pulmonary Disease (COPD) is a chronic respiratory
 disorder characterized by limited airflow, shortness of breath, cough,
 wheezing and increased sputum production, which can restrict a patient's
 ability to perform normal daily activities.  COPD, which includes chronic
 obstructive bronchitis and emphysema, is most commonly caused by smoking.
     The disease frequently progresses without symptoms and is largely under-
 diagnosed.  COPD is often confused with asthma, which can co-exist.  Lung
 function abnormalities develop before symptoms appear, usually around age 45.
 COPD results in permanent damage to the airways and alveolar tissue, though
 airway obstruction progresses slowly over years.
 
     COPD Treatment
     In addition to smoking cessation, the use of bronchodilators is a key
 component of COPD medical management.  Current treatment guidelines recommend
 regular bronchodilator therapy once symptoms become persistent.  Other
 treatments used in managing COPD include steroids, theophylline, antibiotics
 and oxygen.  Still, better treatments are needed to improve compliance, a
 patient's ability to exercise and sleep and to decrease exacerbations so that
 patients can lead more actives lives.
 
     Impact of COPD
 
     *  An estimated 600 million people worldwide suffer from COPD.
     *  COPD claims approximately three million lives each year.
     *  COPD is the fifth-leading cause of death worldwide and is rapidly
        increasing.
     *  In the United States, COPD is the fourth-leading cause of death after
        heart attacks, cancer and stroke, claiming an estimated 100,000 lives
        annually.
     *  COPD is the 12th leading cause of disability worldwide.
     *  In the United States, direct medical costs associated with COPD total
        $14.7 billion annually, with the disease responsible for indirect costs
        of $9.2 billion.
 
     COPD and Smoking
 
     *  Smoking accounts for up to 90 percent of the risk for developing COPD.
     *  15-20 percent of all smokers will develop COPD.
     *  Patients usually have smoked more than 20 cigarettes a day for 20 years
        or more before COPD symptoms develop.
     *  Even passive smoking carries risks, especially for children and those
        chronically exposed.   Among adults, passive smoking is associated with
        a 10-43 percent increase in risk of developing COPD.
 
     Spiriva(R) Profile
     Spiriva(R) (tiotropium) is a new generation, once-daily inhaled
 anticholinergic bronchodilator.  The Spiriva(R) clinical trials program has
 involved more than 3,000 patients worldwide.  Spiriva(R) was shown to be
 highly effective, safe and well tolerated.  The most common side effect was
 dry mouth, which most patients characterized as mild.
     In four one-year studies where Spiriva(R) was compared to placebo or
 ipratropium bromide involving 1,456 COPD patients, 906 of whom received
 Spiriva(R), Spiriva(R) was shown to:
 
     *  Significantly improve lung function, with improvement maintained over a
        one-year period with no loss of efficacy
     *  Significantly improve quality of life parameters
     *  Significantly improve dyspnea (shortness of breath)
 
     Additionally, in combined analysis of these trial, Spiriva(R) showed a
 statistically significant reduction in exacerbations (worsening of COPD
 symptoms such as shortness of breath, which could lead to hospitalization)
 compared to either placebo or ipratropium bromide.
     Spiriva(R) will be administered using the HandiHaler(R), a breath-
 actuated, single-dose dry power inhaler developed by Boehringer Ingelheim
 specifically for the administration of Spiriva(R).  The HandiHaler(R) is
 convenient and easy to use.
 
                     MAKE YOUR OPINION COUNT -- Click Here
 
                http://tbutton.prnewswire.com/prn/11690X82145746
 
 

SOURCE Pfizer Inc
/PRNewswire Interactive News Release/ -- Boehringer Ingelheim and Pfizer Inc
 announced today that they have entered into a long-term worldwide agreement to
 jointly market Spiriva(R) (tiotropium), a novel once-a-day inhaled treatment
 for Chronic Obstructive Pulmonary Disease (COPD), which includes chronic
 bronchitis and emphysema.
     Boehringer Ingelheim has filed for marketing approval with regulatory
 authorities in Europe, where Spiriva(R) could be available as early as mid-
 2002.  A new drug application for Spiriva(R) is anticipated to be filed with
 the Food and Drug Administration later this year.
     Spiriva(R), discovered and developed by Boehringer Ingelheim, would be the
 first once-a-day inhaled bronchodilator treatment for COPD and represents a
 significant advance over other treatment options.   With Atrovent(R) and
 Combivent(R), Boehringer Ingelheim already markets two leading medications for
 COPD worldwide.
     According to the World Health Organization, about 600 million people
 suffer from COPD, though many are undiagnosed.  The disease claims three
 million lives annually.  It is estimated that one in five smokers will develop
 COPD.
     "We're very pleased to be working with Pfizer in co-promoting Spiriva(R),"
 said Prof. Rolf Krebs, Chairman of the Board of Managing Directors at
 Boehringer Ingelheim.  "Through this agreement, we gain a strong and
 experienced partner who will help increase awareness of the disease and of the
 significant patient benefits that this novel compound delivers."
     "We fully expect Spiriva(R) to be an important treatment option for a
 condition that is debilitating to patients and costly to health care systems
 worldwide," said Pfizer Chief Executive Officer Hank McKinnell.  "Building on
 our extensive partnering experience and combined with Boehringer Ingelheim's
 established strength and long experience in respiratory disease management,
 Spiriva(R) should become the global leader in treating COPD."
     COPD is a chronic respiratory disorder characterized by limited airflow
 accompanied by symptoms such as shortness of breath, cough, wheezing and
 increased sputum production.  As the disease progresses, patients become
 increasingly disabled, although at first they may attribute their symptoms to
 aging.  Currently there are no specific medications that are fully effective
 in treating COPD.
     Data from clinical trials involving more than 3,000 patients worldwide
 have demonstrated that Spiriva(R) is highly effective, providing sustained
 bronchodilation with significant symptomatic improvement in shortness of
 breath.  Data also indicate that Spiriva(R) reduced exacerbations of COPD,
 resulting in fewer hospitalizations.  Spiriva(R) also was shown to be well
 tolerated.
     Under terms of the agreement, Boehringer Ingelheim and Pfizer will conduct
 additional clinical trials and further develop Spiriva(R).
     "We anticipate this will be a long and productive collaboration with
 Pfizer in the commercialization of Spiriva(R)," said Dr. Alessandro Banchi,
 Member of Boehringer Ingelheim's Board of Managing Directors who is
 responsible for pharmaceutical marketing and sales.
 
     The Boehringer Ingelheim group of companies, with headquarters in
 Ingelheim, Germany, is one of the 20 leading pharmaceutical companies in the
 world.  In 2000, it posted revenues of more than EUR 6 billion.  Boehringer
 has some 140 affiliated companies worldwide.  The focus is on the human
 pharmaceutical and animal health businesses.  The human pharmaceutical
 business, which accounts for 95 percent of sales, mainly includes prescription
 medicines and products for consumer health care but also products for
 industrial customers (chemicals and biopharmaceuticals).
     Substantial research and development, production, and distribution
 facilities are located around the globe.  In 2000, Boehringer-Ingelheim spent
 EUR 1 billion on research and development, equivalent to 16 percent of net
 sales.
 
     Pfizer Inc discovers, develops, manufactures and markets leading
 prescription medicines for humans and animals, and many of the world's best-
 known consumer products.  Pfizer had global revenues of $29.6 billion in 2000.
 Pfizer plans to make a research and development investment of approximately
 $5 billion in 2001.
 
     COPD FACTS
 
     The Disease
 
     Chronic Obstructive Pulmonary Disease (COPD) is a chronic respiratory
 disorder characterized by limited airflow, shortness of breath, cough,
 wheezing and increased sputum production, which can restrict a patient's
 ability to perform normal daily activities.  COPD, which includes chronic
 obstructive bronchitis and emphysema, is most commonly caused by smoking.
     The disease frequently progresses without symptoms and is largely under-
 diagnosed.  COPD is often confused with asthma, which can co-exist.  Lung
 function abnormalities develop before symptoms appear, usually around age 45.
 COPD results in permanent damage to the airways and alveolar tissue, though
 airway obstruction progresses slowly over years.
 
     COPD Treatment
     In addition to smoking cessation, the use of bronchodilators is a key
 component of COPD medical management.  Current treatment guidelines recommend
 regular bronchodilator therapy once symptoms become persistent.  Other
 treatments used in managing COPD include steroids, theophylline, antibiotics
 and oxygen.  Still, better treatments are needed to improve compliance, a
 patient's ability to exercise and sleep and to decrease exacerbations so that
 patients can lead more actives lives.
 
     Impact of COPD
 
     *  An estimated 600 million people worldwide suffer from COPD.
     *  COPD claims approximately three million lives each year.
     *  COPD is the fifth-leading cause of death worldwide and is rapidly
        increasing.
     *  In the United States, COPD is the fourth-leading cause of death after
        heart attacks, cancer and stroke, claiming an estimated 100,000 lives
        annually.
     *  COPD is the 12th leading cause of disability worldwide.
     *  In the United States, direct medical costs associated with COPD total
        $14.7 billion annually, with the disease responsible for indirect costs
        of $9.2 billion.
 
     COPD and Smoking
 
     *  Smoking accounts for up to 90 percent of the risk for developing COPD.
     *  15-20 percent of all smokers will develop COPD.
     *  Patients usually have smoked more than 20 cigarettes a day for 20 years
        or more before COPD symptoms develop.
     *  Even passive smoking carries risks, especially for children and those
        chronically exposed.   Among adults, passive smoking is associated with
        a 10-43 percent increase in risk of developing COPD.
 
     Spiriva(R) Profile
     Spiriva(R) (tiotropium) is a new generation, once-daily inhaled
 anticholinergic bronchodilator.  The Spiriva(R) clinical trials program has
 involved more than 3,000 patients worldwide.  Spiriva(R) was shown to be
 highly effective, safe and well tolerated.  The most common side effect was
 dry mouth, which most patients characterized as mild.
     In four one-year studies where Spiriva(R) was compared to placebo or
 ipratropium bromide involving 1,456 COPD patients, 906 of whom received
 Spiriva(R), Spiriva(R) was shown to:
 
     *  Significantly improve lung function, with improvement maintained over a
        one-year period with no loss of efficacy
     *  Significantly improve quality of life parameters
     *  Significantly improve dyspnea (shortness of breath)
 
     Additionally, in combined analysis of these trial, Spiriva(R) showed a
 statistically significant reduction in exacerbations (worsening of COPD
 symptoms such as shortness of breath, which could lead to hospitalization)
 compared to either placebo or ipratropium bromide.
     Spiriva(R) will be administered using the HandiHaler(R), a breath-
 actuated, single-dose dry power inhaler developed by Boehringer Ingelheim
 specifically for the administration of Spiriva(R).  The HandiHaler(R) is
 convenient and easy to use.
 
                     MAKE YOUR OPINION COUNT -- Click Here
 
                http://tbutton.prnewswire.com/prn/11690X82145746
 
 SOURCE  Pfizer Inc

RELATED LINKS

http://www.pfizer.com